ARTV
Artiva Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.61
+2.01%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$8.44
From 52W high−35.70%
Volume2.20M
Market cap$420.94M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$8.44
From 52W high
−35.70%
Volume
2.20M
Market cap
$420.94M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
P/E (TTM)
—
RSI (14)
24.0
MomentumView details →
1D Return
+2.01%
YTD Return
+96.60%
SummaryUpdated Jun 1, 2026
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is a clinical-stage biotechnology company founded in 2019 and headquartered in San Diego, California. The company specializes in developing innovative cell-based therapies using natural killer (NK) cells to treat both autoimmune diseases and various forms of cancer. Since its incorporation, Artiva has focused on advancing a pipeline of off-the-shelf and engineered NK cell therapies, with its lead candidate AB-101 currently in clinical development for multiple indications including lupus nephritis, rheumatoid arthritis, and B-cell lymphomas.
Similar companies
Latest newsMore news →
Artiva Biotherapeutics, Inc. elected Brian Daniels, M.D. and Laura Stoppel, Ph.D. as Class II directors effective September 8, 2026.9d agoThe U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Artiva Biotherapeutics' AlloNK plus rituximab for refractory rheumatoid arthritis.104d ago